Clinical Trials Logo

Lung Cancer clinical trials

View clinical trials related to Lung Cancer.

Filter by:

NCT ID: NCT06227897 Not yet recruiting - Lung Cancer Clinical Trials

Aumolertinib in EGFR-Mutant Resected Stage IB-IIIA NSCLC (AERESA).

AERESA
Start date: April 1, 2024
Phase: Phase 2
Study type: Interventional

Aumolertinib (almonertinib; HS-10296) is a novel third-generation EGFR-TKI showing activity against EGFR-sensitizing mutations and EGFR T790M mutation. The third-generation EGFR-TKI osimertinib has been approved in the adjuvant setting. This study is to studying 3-year aumolertinib as adjuvant therapy to see how well it works in treating patients with resected stage IB-IIIA NSCLC harboring sensitizing EGFR mutations.

NCT ID: NCT06202690 Not yet recruiting - Lung Cancer Clinical Trials

SP Robotic Versus VATS Anatomical Pulmonary Resection for Patients With NSCLC

SPORTS
Start date: January 9, 2024
Phase: N/A
Study type: Interventional

Single-POrt Robotic-assisted thoracic surgery versus single-port video-assisted Thoracic Surgery major pulmonary resection for patients with non-small cell lung cancer (SPORTS trial): a single-center, a single blinded, randomized controlled trial

NCT ID: NCT06202222 Not yet recruiting - Lung Cancer Clinical Trials

Interest of Intensive Postoperative Rehabilitation Following Minimally Invasive Lung Resection

IRPOL
Start date: February 1, 2024
Phase: N/A
Study type: Interventional

For patients diagnosed with non-small cell lung cancer (NSCLC), lung resection surgery remains the gold standard for curative treatment. This scheduled operation is associated with significant morbidity, particularly in individuals with impaired cardio-respiratory function. Therefore, patient optimization is paramount. The process begins prior to surgery with preoperative rehabilitation, commonly referred to as "prehabilitation," serving as the foundation for various Enhanced Recovery After Surgery programs. The training methods employed in these programs bear similarity to rehabilitation programs designed for patients with chronic obstructive pulmonary disease (COPD). Postoperatively, patients undergoing thoracic surgery partake in daily physiotherapy sessions, aiming to optimize the postoperative period, minimize the respiratory impact of surgery, and reduce the length of hospital stay. However, this treatment is not currently standardized and primarily involves early mobilization, including walking, and respiratory physiotherapy. Our focus is on the intensity and methods of this postoperative rehabilitation. There is limited literature on effective early rehabilitation in the immediate postoperative period, and existing studies suggest no adverse events associated with postoperative training. Therefore, our objective is to assess whether combining endurance training with standard physiotherapy (walking and respiratory physiotherapy) enhances the functional capacity of individuals undergoing lung surgery.

NCT ID: NCT06196294 Not yet recruiting - Lung Cancer Clinical Trials

GPC3/Mesothelin-CAR-γδT Cells Against Cancers

Start date: January 10, 2024
Phase: Phase 1
Study type: Interventional

The third generation of GPC3/mesothelin targeted CAR-γδT cells have been constructed and their anti-cancer function has been verified by multiple in vitro and in vivo studies. Clinical studies will be performed to test anti-cancer function of the CAR-γδT cells for immunotherapy of human cancer patients with GPC3 or Mesothelin expressions. In this phase I study, the safety, tolerance, and preliminary efficacy of the GPC3/Mesothelin-CAR-γδT cell immunotherapy on human cancers will firstly be evaluated.

NCT ID: NCT06187103 Not yet recruiting - Breast Cancer Clinical Trials

Evaluation of Improved Onboard Patient Imaging

Start date: May 2024
Phase: N/A
Study type: Interventional

The primary objective of radiation therapy is to deliver a therapeutic dose of radiation precisely to the target while minimizing exposure to healthy surrounding tissues. Image-guided radiation therapy (IGRT) involves acquiring cone beam computed tomography (CBCT) scans just before or during treatment sessions. By comparing the CBCT images with the reference images from the treatment planning process, clinicians can make necessary adjustments to ensure precise targeting and account for any changes that may have occurred since the initial planning. Conventional CBCT technology is, however, limited by several factors including long acquisition times that result in motion artifacts in the image, smaller fields of view that limit the volume of anatomy that can be imaged, poor image quality that limits soft tissue visibility, and artifacts created by dense metal implants. This study will evaluate a novel CBCT imaging solution ("HyperSight") that has the potential to address the challenges of conventional CBCT.

NCT ID: NCT06157957 Not yet recruiting - Lung Cancer Clinical Trials

Cancer Screening Smoking Cessation AND Respiratory Assessment

CASSANDRA
Start date: December 31, 2023
Phase: N/A
Study type: Interventional

The CASSANDRA project (Cancer Screening, Smoking Cessation, AND Respiratory Assessment) is a project led by SEPAR whose main coordinators are Dr. Luis Seijo, a pulmonologist at the Clínica Universitaria de Navarra, and Dr. Juan Carlos Trujillo-Reyes, a thoracic surgeon at the Hospital de la Santa Creu I Sant Pau and Coordinator of the Thoracic Oncology Area, in addition to the collaboration of a large number of professionals with expertise in lung cancer screening. Despite its proven efficacy, Spain does not yet have a unified lung cancer screening protocol. The aim of the CASSANDRA project is to initiate a national screening program that can join forces with existing smoking cessation programs in Spain, which have proven to be insufficient in reducing the number of people affected by lung cancer. CASSANDRA aims to analyze the feasibility of implementing a lung cancer screening program in Spain implemented in the public health system and carry out a cost-effectiveness analysis

NCT ID: NCT06141005 Not yet recruiting - Lung Cancer Clinical Trials

Feasibility of Bronchial Washing Fluid for Molecular Testing With Next Generation Sequencing in Lung Cancer

Start date: November 30, 2023
Phase: N/A
Study type: Interventional

This is a single center, clinical trial evaluating the relevance of intratumoral washing for detection of generic alteration with Next Generation Sequencing.

NCT ID: NCT06127654 Not yet recruiting - Lung Cancer Clinical Trials

Ventilation Imaging to Improve the Quality of Life for Patients With Lung Cancer Treated With Radiation Therapy

VITaL
Start date: December 2023
Phase: Phase 3
Study type: Interventional

This research project is testing a new treatment planning method for patients with lung cancer who will be treated with radiation therapy. This new method is called Computed Tomography (CT) ventilation imaging. It aims to help protect the healthiest parts of patient's lungs from being injured by the radiation therapy. The investigators will determine whether healthy lung sparing can improve the quality of life in these patients.

NCT ID: NCT06115447 Not yet recruiting - Lung Cancer Clinical Trials

Polypropylene vs Polyglactin in Suturing of the Lung

Start date: April 15, 2024
Phase:
Study type: Observational

Comparative study comparing polypropylene and Polyglactin in suturing of the lung

NCT ID: NCT06105801 Not yet recruiting - Lung Cancer Clinical Trials

TBNA vs EBUS-TBNA Plus Transbronchial Mediastinal Cryobiopsy for Adequacy of Next Generation Sequencing

META-Gen
Start date: October 31, 2024
Phase: Phase 3
Study type: Interventional

This is a multi-center, clinical trial evaluating the effect of adding transbronchial mediastinal cryobiopsy to EBUSTBNA for its ability to improve the likelihood of obtaining tissue sufficient for molecular analysis. Patients in outpatient clinics or pre-operative holding areas planning to undergo a bronchoscopic biopsy of a suspected malignant lesion (peripheral or mediastinal) for initial diagnosis, staging, or acquisition of tissue for molecular analysis will be considered for enrollment and consented. Patients will only be enrolled if intraoperative ROSE of a mediastinal 8 lymph node or mass suggests malignancy. Patients will be randomized to continue with the operator's initial EBUS-TBNA needle or switch to a cryoprobe to perform a transbronchial mediastinal cryobiopsy.